BS_V72H4RQS
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 9.231274638633376
- age_years
- 4.795
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.691
- G2M_CHECKPOINT+0.665
- MYC_TARGETS_V1+0.533
- MYC_TARGETS_V2+0.493
- DNA_REPAIR+0.370
- MITOTIC_SPINDLE+0.321
- TGF_BETA_SIGNALING+0.269
- WNT_BETA_CATENIN_SIGNALING+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.203
- SPERMATOGENESIS+0.183
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.498
- INTERFERON_GAMMA_RESPONSE-0.486
- INTERFERON_ALPHA_RESPONSE-0.481
- TNFA_SIGNALING_VIA_NFKB-0.475
- IL6_JAK_STAT3_SIGNALING-0.471
- INFLAMMATORY_RESPONSE-0.431
- P53_PATHWAY-0.387
- APICAL_SURFACE-0.372
- COMPLEMENT-0.367
- ESTROGEN_RESPONSE_EARLY-0.332
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_D144EJRQ | medulloblastoma | — | 0.936 |
| 2 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.925 |
| 3 | C3N-03076 | — | cohortMD1 | 0.920 |
| 4 | BS_HE57E1RP | medulloblastoma | — | 0.920 |
| 5 | SRR12475147 | — | — | 0.908 |
| 6 | BS_5P1TN10Z | Embryonal tumors | — | 0.905 |
| 7 | MDT-AP-0164 | Med | Medulloblastoma | 0.905 |
| 8 | BS_GCQFGDTX | medulloblastoma | — | 0.902 |
| 9 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.901 |
| 10 | BS_TV5B86ZD | Embryonal tumors | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.691 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.665 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.533 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.493 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.321 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.269 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.203 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.183 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.169 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.066 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.066 | Remibrutinib | — uncovered |